These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 26982718)

  • 1. Drug monitoring and individual dose optimization of antimicrobial drugs: oxazolidinones.
    Cattaneo D; Alffenaar JW; Neely M
    Expert Opin Drug Metab Toxicol; 2016 May; 12(5):533-44. PubMed ID: 26982718
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug-drug interactions and safety of linezolid, tedizolid, and other oxazolidinones.
    Douros A; Grabowski K; Stahlmann R
    Expert Opin Drug Metab Toxicol; 2015; 11(12):1849-59. PubMed ID: 26457865
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tedizolid (torezolid) for the treatment of complicated skin and skin structure infections.
    Carena AA; Stryjewski ME
    Expert Rev Clin Pharmacol; 2020 Jun; 13(6):577-592. PubMed ID: 32449440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tedizolid: a novel oxazolidinone with potent activity against multidrug-resistant gram-positive pathogens.
    Zhanel GG; Love R; Adam H; Golden A; Zelenitsky S; Schweizer F; Gorityala B; Lagacé-Wiens PR; Rubinstein E; Walkty A; Gin AS; Gilmour M; Hoban DJ; Lynch JP; Karlowsky JA
    Drugs; 2015 Feb; 75(3):253-70. PubMed ID: 25673021
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonclinical and pharmacokinetic assessments to evaluate the potential of tedizolid and linezolid to affect mitochondrial function.
    Flanagan S; McKee EE; Das D; Tulkens PM; Hosako H; Fiedler-Kelly J; Passarell J; Radovsky A; Prokocimer P
    Antimicrob Agents Chemother; 2015 Jan; 59(1):178-85. PubMed ID: 25331703
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tedizolid (TR-701): a new oxazolidinone with enhanced potency.
    Kanafani ZA; Corey GR
    Expert Opin Investig Drugs; 2012 Apr; 21(4):515-22. PubMed ID: 22324973
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thrombocytopenia with Tedizolid and Linezolid.
    Lee EY; Caffrey AR
    Antimicrob Agents Chemother; 2018 Jan; 62(1):. PubMed ID: 29038274
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Sterilizing Effect of Intermittent Tedizolid for Pulmonary Tuberculosis.
    Srivastava S; Deshpande D; Nuermberger E; Lee PS; Cirrincione K; Dheda K; Gumbo T
    Clin Infect Dis; 2018 Nov; 67(suppl_3):S336-S341. PubMed ID: 30496463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Linezolid for the treatment of resistant gram-positive cocci.
    Bain KT; Wittbrodt ET
    Ann Pharmacother; 2001 May; 35(5):566-75. PubMed ID: 11346064
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prolonged use of tedizolid in a pulmonary non-tuberculous mycobacterial infection after linezolid-induced toxicity.
    Yuste JR; Bertó J; Del Pozo JL; Leiva J
    J Antimicrob Chemother; 2017 Feb; 72(2):625-628. PubMed ID: 27999019
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of the microbiological efficacy of tedizolid and linezolid in acute bacterial skin and skin structure infections: pooled data from phase 3 clinical trials.
    Corey R; Moran G; Goering R; Bensaci M; Sandison T; De Anda C; Prokocimer P
    Diagn Microbiol Infect Dis; 2019 Jul; 94(3):277-286. PubMed ID: 30940414
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tedizolid and Linezolid for Treatment of Acute Bacterial Skin and Skin Structure Infections of the Lower Extremity versus Non-Lower-Extremity Infections
    Joseph WS; Culshaw D; Anuskiewicz S; De Anda C; Prokocimer P
    J Am Podiatr Med Assoc; 2017 Jul; 107(4):264-271. PubMed ID: 27533787
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial.
    Moran GJ; Fang E; Corey GR; Das AF; De Anda C; Prokocimer P
    Lancet Infect Dis; 2014 Aug; 14(8):696-705. PubMed ID: 24909499
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Pharmacokinetics and Pharmacodynamics of Oxazolidinones.
    Roger C; Roberts JA; Muller L
    Clin Pharmacokinet; 2018 May; 57(5):559-575. PubMed ID: 29063519
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Linezolid in the treatment of drug-resistant tuberculosis: the challenge of its narrow therapeutic index.
    Wasserman S; Meintjes G; Maartens G
    Expert Rev Anti Infect Ther; 2016 Oct; 14(10):901-15. PubMed ID: 27532292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of the phase 3 ESTABLISH trials of tedizolid versus linezolid in acute bacterial skin and skin structure infections.
    Shorr AF; Lodise TP; Corey GR; De Anda C; Fang E; Das AF; Prokocimer P
    Antimicrob Agents Chemother; 2015 Feb; 59(2):864-71. PubMed ID: 25421472
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early experience with tedizolid: clinical efficacy, pharmacodynamics, and resistance.
    Rybak JM; Marx K; Martin CA
    Pharmacotherapy; 2014 Nov; 34(11):1198-208. PubMed ID: 25266820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics, Pharmacodynamics, and Tolerability of Single-Dose Oral LCB01-0371, a Novel Oxazolidinone with Broad-Spectrum Activity, in Healthy Volunteers.
    Cho YS; Lim HS; Lee SH; Cho YL; Nam HS; Bae KS
    Antimicrob Agents Chemother; 2018 Jul; 62(7):. PubMed ID: 29712654
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An in vitro evaluation of the efficacy of tedizolid: implications for the treatment of skin and soft tissue infections.
    Delpech P; ALeryan M; Jones B; Gemmell C; Lang S
    Diagn Microbiol Infect Dis; 2018 May; 91(1):93-97. PubMed ID: 29452993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of tedizolid in skin and soft tissue infections.
    Bouza E; Muñoz P; Burillo A
    Curr Opin Infect Dis; 2018 Apr; 31(2):131-140. PubMed ID: 29346119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.